Virological Changes of Chronic Hepatitis B Patients with Minimally Elevated Levels of Alanine Aminotransferase: A Meta-Analysis and Systematic Review
暂无分享,去创建一个
Boxiang Zhang | L. Peng | C. Xie | Hewei Wu | Xingrong Zheng | Xiyao Chen
[1] G. Wan,et al. Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients , 2022, Virologica Sinica.
[2] Liang Chen,et al. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection , 2021, EBioMedicine.
[3] Jaw-Town Lin,et al. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. , 2021, The Lancet. Infectious diseases.
[4] [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
[5] Q. Ning,et al. Roadmap to functional cure of chronic hepatitis B: An expert consensus , 2019, Journal of viral hepatitis.
[6] I. Oh,et al. Serum alanine aminotransferase level and liver‐related mortality in patients with chronic hepatitis B: A large national cohort study , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[7] S. Alavian,et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.
[8] Da-wei Chen,et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. , 2018, Journal of hepatology.
[9] S. Kottilil,et al. Chronic Hepatitis B Infection: A Review , 2018, JAMA.
[10] P. Hu,et al. Systematic review with meta‐analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance , 2018, Alimentary pharmacology & therapeutics.
[11] B. McMahon,et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance , 2018, Hepatology.
[12] P. Lampertico,et al. Treatment of hepatitis B: Is there still a role for interferon? , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[13] Xinyue Chen,et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated‐interferon alpha , 2017, Hepatology.
[14] R. Takkenberg,et al. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. , 2017, The lancet. Gastroenterology & hepatology.
[15] Shigui Yang,et al. Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients , 2017, World journal of gastroenterology.
[16] Chien-Jen Chen,et al. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis , 2016, Medicine.
[17] P. Hu,et al. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[18] M. Buti,et al. Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. , 2016, Gastroenterology.
[19] M. Kumar,et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.
[20] Yue Chen,et al. Effect of Peg‐interferon α‐2a combined with Adefovir in HBV postpartum women with normal levels of ALT and high levels of HBV DNA , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[21] Wenhong Zhang,et al. Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment , 2015, Antimicrobial Agents and Chemotherapy.
[22] L. Nguyen,et al. Histologic changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] H. Chan,et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. , 2014, Gastroenterology.
[24] L. Nguyen,et al. Systematic review with meta‐analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤40 IU/L and significant hepatic fibrosis , 2014, Alimentary pharmacology & therapeutics.
[25] H. Lee,et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability , 2013, Gut.
[26] Chien-Jen Chen,et al. Natural history of chronic hepatitis B REVEALed , 2011, Journal of gastroenterology and hepatology.
[27] Benjamin J. Hyatt,et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. , 2007, Journal of hepatology.
[28] A. Zanella,et al. Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels , 2002, Annals of Internal Medicine.
[29] E. Schiff,et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.